TY - JOUR
T1 - Neuroprotective effects of Withania somnifera on 6-hydroxydopamine induced Parkinsonism in rats
AU - Ahmad, Muzamil
AU - Saleem, Sofiyan
AU - Ahmad, Abdullah Shafique
AU - Ansari, Mubeen Ahmad
AU - Yousuf, Seema
AU - Hoda, Md Nasrul
AU - Islam, Fakhrul
PY - 2005/3
Y1 - 2005/3
N2 - 6-Hydroxydopamine (6-OHDA) is one of the most widely used rat models for Parkinson's disease. There is ample evidence in the literature that 6-OHDA elicits its toxic manifestations through oxidant stress. In the present study, we evaluated the anti-parkinsonian effects of Withania somnifera extract, which has been reported to have potent anti-oxidant, anti-peroxidative and free radical quenching properties in various diseased conditions. Rats were pretreated with 100, 200 and 300 mg/kg b.w. of the W. somnifera extract orally for 3 weeks. On day 21, 2 μL of 6-OHDA (10 μg in 0.1% in ascorbic acid-saline) was infused into the right striatum while sham operated group received 2 μL of the vehicle. Three weeks after 6-OHDA injections, rats were tested for neurobehavioral activity and were killed 5 weeks after lesioning for the estimation of lipidperoxidation, reduced glutathione content, activities of glutathione-S-transferase, glutathione reductase, glutathione peroxidase, superoxide dismutase and catalase, catecholamine content, dopaminergic D 2 receptor binding and tyrosine hydroxylase expression. W. somnifera extract was found to reverse all the parameters significantly in a dose-dependent manner. Thus, the study demonstrates that the extract of W. somnifera may be helpful in protecting the neuronal injury in Parkinson's disease.
AB - 6-Hydroxydopamine (6-OHDA) is one of the most widely used rat models for Parkinson's disease. There is ample evidence in the literature that 6-OHDA elicits its toxic manifestations through oxidant stress. In the present study, we evaluated the anti-parkinsonian effects of Withania somnifera extract, which has been reported to have potent anti-oxidant, anti-peroxidative and free radical quenching properties in various diseased conditions. Rats were pretreated with 100, 200 and 300 mg/kg b.w. of the W. somnifera extract orally for 3 weeks. On day 21, 2 μL of 6-OHDA (10 μg in 0.1% in ascorbic acid-saline) was infused into the right striatum while sham operated group received 2 μL of the vehicle. Three weeks after 6-OHDA injections, rats were tested for neurobehavioral activity and were killed 5 weeks after lesioning for the estimation of lipidperoxidation, reduced glutathione content, activities of glutathione-S-transferase, glutathione reductase, glutathione peroxidase, superoxide dismutase and catalase, catecholamine content, dopaminergic D 2 receptor binding and tyrosine hydroxylase expression. W. somnifera extract was found to reverse all the parameters significantly in a dose-dependent manner. Thus, the study demonstrates that the extract of W. somnifera may be helpful in protecting the neuronal injury in Parkinson's disease.
KW - 6-hydroxydopamine
KW - Antioxidant
KW - Dopamine
KW - Oxidative stress
KW - Parkinson's disease
KW - Withania somnifera
UR - http://www.scopus.com/inward/record.url?scp=18044398197&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=18044398197&partnerID=8YFLogxK
U2 - 10.1191/0960327105ht509oa
DO - 10.1191/0960327105ht509oa
M3 - Article
C2 - 15901053
AN - SCOPUS:18044398197
SN - 0960-3271
VL - 24
SP - 137
EP - 147
JO - Human and Experimental Toxicology
JF - Human and Experimental Toxicology
IS - 3
ER -